YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Intellia Therapeutics, Inc. (NTLA) shares rallied 7.6% in the last trading session to close at $12.6. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to t…
Nike downgraded, Home Depot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Cathie Wood-led Ark Invest trimmed its position in Palantir Technologies Inc. on Thursday, as the artificial intelligence software company…
This article first appeared on GuruFocus. Gene-editing stocks fell Wednesday after Anthropic's Claude AI model identified an enzyme system with characteristics similar to technology used to alter DNA. Beam Therapeutics (BEAM), CRISPR Thera…
Key Points Interested in Intellia Therapeutics, Inc.? Here are five stocks we like better. Lonvo-z's FDA decision is scheduled for March 10 following priority review of Intellia's hereditary angioedema application, with no advisory committ…
Company Logo The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV…
Intellia Therapeutics NTLA leverages its proprietary technologies and expertise, including CRISPR-based gene-editing technologies, oligonucleotides and lipid nanoparticles (LNPs), to develop novel, first-in-class therapeutic candidates. Th…
This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical doll…
Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when she sees a new opportunity. That's what she did last week, pouring $27.9 million into Meta Platforms (META) as the company pushes deeper into AI. Last…
Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement.…
Cathie Wood, chief of Ark Investment Management, likes to chase momentum in her favorite tech bets. This week, she's buying $6.5 million of Cerebras stock as the AI chip stock surges. Last year, the flagship Ark Innovation ETF gained 35.49…
Intellia Therapeutics NTLA announced that the FDA has accepted the biologics license application (BLA) seeking approval for lonvoguran ziclumeran (lonvo-z; formerly NTLA-2002), an in vivo CRISPR-based gene-editing therapy, for the treatmen…
An updated edition of the July 20, 2026, article. Genomics is a comprehensive study of genomes (an organism's complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this area have heightened interest from pharmaceutic…
Cathie Wood, chief of Ark Investment Management, often adds to her favorite stocks when prices swing. This time, according to an email shared with TheStreet, she's buying $3.5 million of Robinhood stock, reversing her recent sales as the o…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s Ark Invest leaned further into high-growth themes, including space, fintech, crypto, and biotechnology…
Intellia Therapeutics recently entered into a US$400 million non-dilutive senior secured term loan facility with OrbiMed, including a US$75 million initial draw and milestone-based tranches primarily linked to lonvoguran ziclumeran (lonvo-…
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its "Small Cap Strategy". The letter can be downloaded here. The strategy returned 24.01% in the second quarter, outperforming the Ru…
Company Logo 170-Page Report Tracks Intellia and Regeneron's Nex-Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR Treatment Dublin, Sept. 04, 2026 (GLOBE NEWSWIRE) --…
Heading into the final third of the year, Cathie Wood isn't trading in her racing stripes. The founder, CEO, and chief investment officer at Ark Invest continues to outfit her collection of exchange-traded funds with aggressive growth oppo…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its genetic source rather than primarily managing downstream symptoms. Unlike conventional therapies that may require chro…
Cathie Wood's ARK Invest made big buys of SpaceX stock across multiple ETFs on Friday. SpaceX is firm's second-largest investment, behind only Tesla. Continue Reading
Cathie Wood, head of Ark Investment Management, often adds to her favorite tech stocks when prices swing. This week, she's buying SpaceX (SPCX), continuing to build her position after the newly public stock went through a volatile stretch…
Quick Read Moderna's 177% stock surge to a ~$70B market cap makes ABUS a prime target, as buying it eliminates $1.3B in LNP patent exposure. NTLA's Phase 3 lonvo-z showed 87% fewer hereditary angioedema attacks, while EDIT offers cardiomet…
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Biotech stocks have reached their highest level since the height of the pandemic after Moderna (MRNA [ht…
This article first appeared on GuruFocus. The supplied source only contains the heatmap headline and ticker list, without the underlying short-interest percentages or ranking data. I can write the story accurately from that limited informa…
Intellia Therapeutics NTLA incurred a second-quarter 2026 loss of 80 cents per share, in line with the Zacks Consensus Estimate. The loss narrowed 18.4% from the loss of 98 cents per share in the year-ago quarter. Intellia's total revenues…
Key Points Interested in Intellia Therapeutics, Inc.? Here are five stocks we like better. Lonvo-z delivered strong Phase III results in hereditary angioedema, reducing monthly attacks by 87% versus placebo; 62% of treated patients were at…
This article first appeared on GuruFocus. Cash Position: Cash, equivalents, and marketable securities totaled $628.4 million as of June 30, 2026, up from $605.1 million at the end of 2025. Cash Runway: Company expects current cash balance…
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to a loss of $0.55 per share a year ago. These figures are adjusted for non-recurri…
An updated edition of the June 2, 2026, article. Genomics is a broad and detailed study of genomes (an organism's complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this area have heightened interest from pharmace…
Shares of Intellia Therapeutics NTLA have rallied sharply over the past month, supported by positive regulatory and clinical milestones for one of its lead candidates, lonvoguran ziclumeran (lonvo-z; formerly NTLA-2002), as well as continu…
Oselote/iStock via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Alnylam Pharma (ALNY [https://seekingalpha.com/symbol/ALNY]), and BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]), which market drugs for a…
Bull and bear on a tablet_Image by Ice stocker via Shutterstock Wolfspeed (WOLF) has spent the last year trying to convince investors that its turnaround story is real. Its overhaul included new leadership, a reorganized go-to-market plan,…
Key Points Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals. That could eventually create huge opportunities for new programs for the biotechs. 10 st…